Teleflex Incorporated


SKU: TFX Category:


This is our first report on Teleflex, one of the largest manufacturers of single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications. The company had a mixed performance in the last quarter with revenues of $686.8 million, below Wall Street expectations. However, it did manage to produce an earnings beat. The company’s high-growth revenue, which includes UroLift, MANTA, hemostatic products, EZ-IO, on controls, and PIC, maintained pace across most growth drivers. UroLift has decreased by 5.8% over the past nine months, while the remaining products in the high-growth portfolio continue to post healthy gains of 14%. During the third quarter, they continued to notice signs of a severe supply-chain interruption. Select raw materials and components are still not all back to expected availability. The company also saw good results across its diverse portfolio, with complicated catheters, MANTA, and balloon pumps on control, contributing to growth. Furthermore, Teleflex relaunched the Langston Dual Lumen Catheter, and it anticipates that sales will pick up in the fourth quarter and continue until 2023. They also featured the Karolinska 1000 consecutive MANTA device trial at the TCT conference. The management is eager to use virtual reality to improve the interaction of their sales force and medical training. We initiate coverage on the stock of Teleflex Incorporated with a ‘Hold’ rating.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!